Novartis | NOVN - Créanciers Commerciaux





Créanciers Commerciaux Changement Date
AbbVie USD 3.59B 28.65B 2025-12
Alcon AG USD 926M 31M 2025-12
Almirall EUR 258.05M 58.66M 2025-12
Amgen USD 20.89B 1.25B 2025-12
AstraZeneca USD 25.28B 252M 2025-12
Autolus Therapeutics Ltd USD 3.08M 7.88M 2025-12
Bayer EUR 7.08B 700M 2025-12
Biogen USD 432M 18.9M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Eli Lilly USD 5.38B 1.12B 2025-12
Fresenius EUR 1.08B 65M 2025-09
Fresenius Medical Care EUR 835.55M 109.7M 2025-12
Galapagos EUR 104.65M 4.02M 2025-12
Genmab DKK 6M 2M 2025-09
Gilead Sciences USD 808M 226M 2025-09
GlaxoSmithKline GBP 15.38B 294M 2025-12
GRIFOLS EUR 841M 37.68M 2025-12
Hikma Pharmaceutical USD 715M 104M 2025-12
J&J USD 11.99B 2.37B 2025-12
Lonza CHF 471M 3M 2024-12
Merck EUR 2.11B 182M 2025-12
Merck USD 4.15B 102M 2025-09
Novartis USD 4.46B 99M 2025-12
Novartis USD 4.46B 99M 2025-12
Novo Nordisk DKK 19.76B 4.15B 2025-12
Orion EUR 123.5M 35.9M 2025-12
Pfizer USD 5.02B 142M 2025-09
Philips EUR 1.93B 214M 2025-12
Recordati EUR 315.05M 15.17M 2025-09
Regeneron Pharmaceuticals USD 5.83B 4.93B 2025-12
Roche Holding CHF 5.78B 1.27B 2025-12
Sanofi EUR 22.93B 927M 2025-12
UCB EUR 4.04B 755M 2025-12